Table 1 Clinicopathologic findings according to the pathological response.
Characteristic | Total (n = 290) | pCR (n = 145) | non-pCR (n = 145) | p-value |
|---|---|---|---|---|
Age (y, mean ± standard deviation) | 50.5 ± 9.5 | 50.9 ± 9.5 | 50.1 ± 9.5 | 0.4664 |
Clinical TNM stage | 0.0188 | |||
II | 150 | 85 (56.7) | 65 (43.3) | |
III | 140 | 60 (42.9) | 80 (57.1) | |
Clinical T stage | 0.1566 | |||
1 | 8 | 4 (50.0) | 4 (50.0) | |
2 | 208 | 112 (53.9) | 96 (46.2) | |
3 | 61 | 25 (41.0) | 36 (59.0) | |
4 | 13 | 4 (30.8) | 9 (69.2) | |
Histologic type | 0.6842 | |||
Invasive ductal carcinoma | 284 | 143 (50.4) | 141 (49.7) | |
Others | 6 | 2 (33.3) | 4 (66.7) | |
Histologic grade | 0.0103 | |||
1 | 1 | 1 (100.0) | 0 (0.0) | |
2 | 109 | 43 (39.5) | 66 (60.6) | |
3 | 175 | 97 (55.4) | 78 (44.6) | |
Unknown | 5 | 4 (80.0) | 1 (20.0) | |
HR (ER and/or PgR) | 0.0197 | |||
Negative | 187 | 103 (55.1) | 84 (44.9) | |
Positive | 103 | 42 (40.8) | 61 (59.2) | |
HER2 | 0.0619 | |||
Negative | 97 | 41 (42.3) | 56 (57.7) | |
Positive | 193 | 104 (53.9) | 89 (46.1) | |
Subtype | < 0.0001 | |||
HR-HER2− | 97 | 41 (42.3) | 56 (57.7) | |
HR-HER2 + | 90 | 62 (68.9) | 28 (31.1) | |
HR + HER2 + | 103 | 42 (40.8) | 61 (59.2) | |
Chemotherapy regimen | 0.0109 | |||
Anthracycline + taxane | 174 | 84 (48.3) | 90 (51.7) | |
Anthracycline + taxane + platinum | 45 | 16 (35.6) | 29 (64.4) | |
Taxane + platinum | 71 | 45 (63.4) | 26 (36.6) | |
Breast surgery | 0.7745 | |||
Breast-conserving surgery | 228 | 115 (50.4) | 113 (49.6) | |
Total mastectomy | 62 | 30 (48.4) | 32 (51.6) |
